Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Iron Med RX vs Lttl

Iron Med RX
Graded #453

Lower grade

vs+11.299999999999997
Lttl
Graded #204

Higher grade

The verdict

Lttl takes it — 66.1/100 to 54.8/100.

Lttl grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Lttl (pronounced 'little') is a direct-to-consumer telehealth brand offering compounded semaglutide and tirzepatide, a low-dose 'microdose' line, and longevity peptides.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueLttl +11
45
56
Dose & formulationLttl +45
51
96
Clinical oversightLttl +5
71
76
Labs & monitoringEven
52
52
FulfillmentLttl +11
58
69
Contract termsIron Med RX +35
55
20
Iron Med RX · left barLttl · right bar

The numbers

MetricIron Med RXLttl
WeighScore54.8/10066.1/100
GradeCC
Scorecard rank#453#204
SemaglutideNot disclosed$199/mo (all doses, compounded)
TirzepatideNot disclosed$279/mo (all doses, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualYesYes
Iron Med RX

Graded #453 · C

Strengths

  • Unusually broad GLP-1 lineup — compounded semaglutide and tirzepatide in both oral tablets and injection, plus microdosing and longevity add-ons
  • Online process with licensed-provider oversight, virtual consults, progress tracking and home delivery
  • Oral tablet options for people who would rather not inject

Where it loses points

  • Prices are not shown publicly — you only see costs after creating an account, so you cannot compare value upfront
  • Labels its oral semaglutide 'research-grade' — wording usually tied to research/non-prescription peptides; confirm it is prescribed for human use
  • Does not name its compounding pharmacy or list the states it serves; the listed address is a private mailbox (PMB), not a clinic
  • Compounded GLP-1 only — no brand-name or insurance options; small, lightly documented operation
Lttl

Graded #204 · C

Strengths

  • Publishes the full price matrix — every medication, form and commitment length — on a public /plans page before checkout
  • Flat dose pricing: 'Same price at every dose,' so moving to a higher dose does not raise the monthly bill
  • States plainly that its compounded GLP-1s 'are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality'
  • Microdose line prices low-dose semaglutide or tirzepatide at $149/mo month-to-month for people sensitive to side effects
  • Oral ODT semaglutide offered for members who want to avoid injections

Where it loses points

  • Partner pharmacies are never named — the site refers only to 'a partner U.S. pharmacy' (a material disclosure gap for a YMYL purchase)
  • The advertised 'Plans start at $129/mo' is the 12-month prepay rate; true month-to-month is $199 semaglutide and $279 tirzepatide
  • No public list of states served — eligibility depends on where unnamed 'partner providers are licensed'
  • Site banner promises 'Prescribed and shipped within 48 hours' while the shipping policy states 2-5 business days to process plus 3-7 to deliver
  • Medications cannot be returned or refunded once they ship from the pharmacy

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard